Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1 Paris, April 28, 2022 Q1 2022 sales growth of 8.6% at CER driven by Dupixent and CHC
/PRNewswire/ More than 28,000 children in the U.S. are currently battling a brain tumor, the deadliest childhood cancer and most common solid cancer in.